Even if years away, funding allows for fast development on Biotech.
Hanaphy 20 [Paul ; 5/28/20; Kingston University Masters degree ; “BRINTER RAISES €1.2M TO FUND LAUNCH OF SCALABLE BIOPRINTER IN NEW MARKETS,” https://3dprintingindustry.com/news/author/paul-hanaphy/]
Funding international growth According to Brinter, many researchers still use traditional drug discovery and disease modelling methods, when its proprietary 3D bioprinter could help scale the entire process. As a result, using its newly-raised funding, the company aims to make its technology as accessible as possible, and bring bioprinting within reach for all U.S. or European clinical firms, hospitals and universities. At present, Brinter’s clientele includes companies like Nanoform, as well as researchers at VTT, the University of Glasgow, Johannes Gutenberg University of Mainz, University of Oulu and University of Helsinki. In one particularly promising project at the University of Eastern Finland, the firm’s technology is currently being used to 3D print neural matter for future brain disease modelling applications. “I am extremely excited to continue our 3D brain printing project with Brinter,” explained Jari Koistinaho, Professor of Regenerative Medicine at the University of Eastern Finland. “3D bioprinting will soon provide us with fine-tuned human mini-brains and brain prosthetics, thereby deepening our understanding of the human mind and our ability to combat serious brain disorders.” For its part, Innovestor has also identified “accelerated technological, material and methodological” advances within the bioprinting industry, and it now anticipates that Brinter’s technology will supplement this trend, making scientific R&D up to ten times faster and helping to usher in the age of bioprinted heart/kidney transplants. “We are very excited to be a part of Brinter’s journey,” concluded Wilhelm Lindholm, CEO of Innovestor. “Brinter is an exciting addition to our portfolio as the company’s competitive advantages of multi-material printing capabilities, modularity, and scalability combined with their own easy-to-use software application were very convincing.” “COMPANIES LIKE BRINTER ARE PAVING THE WAY FOR 3D BIOPRINTING, REVOLUTIONIZING THE FUTURE OF MEDICINE TO THE POINT WHERE A CUSTOMIZED HEART OR KIDNEY CAN BE MADE FOR A TRANSPLANT PATIENT.” Advances in bioprinted organs While transplantable bioprinted organs remain years away from reality, recent advances in the technology may have shortened this wait considerably. 3D Systems’ continued interest in bioprinting will no doubt hasten its development, and the firm reported “tremendous progress” within its dedicated Print to Perfusion program earlier this year. As part of a strategic refocus announced by the company in 2020, it has also sought to build on its core healthcare and industrial segments, and acquired Additive Works and bioprinting firm Allevi during May 2021, with this in mind. Similarly, manufacturers such as UpNano are increasingly entering the bioprinting sector, and the company has now launched its own NanoOne Bio system. Released in May 2021, the firm’s machine is reportedly capable of constructing 3D tissues out of living cells, resulting in viable meso-to-nanoscale sized structures. In more experimental developments, the National Science Foundation (NSF) has awarded Allegro 3D nearly $1 million to fund the R&D of its novel high-throughput bioprinting platform. Using the capital, the firm aims to create a machine that’s capable of rapidly producing in-vitro therapeutic and biomedical testing models.